The 2014 Pathology Congress : Not too late to submit a poster


This event has an open oral and poster session.  Abstracts can be submitted on any subject related to pathology

Abstracts for poster presentation only can be submitted up to two weeks before the event.

You can download the instructions for authors at

02 December 2014 – 04 December 2014

This meeting draws together international experts to discuss current techniques and research involved in cellular and molecular pathology.  This year focuses on four specific areas

  • Progress in Molecular and Cellular Pathology
  • Developments in Immunohistochemistry for Diagnostic Cellular Pathology
  • Biomarkers
  • Histopathology and Cytopathology: Advances in research and techniques

With plenty of opportunity  for networking and debate, this informal international  meeting will bring you up to date with current research and thinking regarding pathology.  This meeting gathers together workings from clinical, academic and pharmaceutical organisations.

This event  has CPD accreditation

Program Outline
 Day 1: Progress in Molecular and Cellular Pathology
This session will discuss current topics presented by experts in their fields of research and practice. Placed in the context of molecular cellular pathology presentations will explore disease mechanisms, clinical advances and latest technology breakthroughs.

Day 2: Developments in immunohistochemistry for diagnostic cellular pathology Developments in Immunohistochemistry (IHC) techniques and technology to aid the improvements needed to boost and strengthen the use of IHC in future diagnostic pathology practice will be discussed

Day 3: 
Morning:  Biomarkers
Biomarkers identifying biological and physiological entities associated with disease are taking an increasingly important place at the tables of drug discovery and personalised medicine. Their discovery in biosamples requires the combined use of genomics, proteomics and bioinformatics platforms. Whilst for their application, robust techniques combining exquisite sensitivity and specificity must be developed. This conference is focused on technologies that are driving advances in this area and their application at gene and expression level in solid and fluid biosamples. As such this session is targeted to provide leading edge information to researchers within the academic, biotechnology and pharmaceutical sectors.

Afternoon:  Histopathology and Cytopathology: Advances in research and techniques

Drawing together international experts to discuss the need for technical-based updates in the areas of immunohistochemistry and cytopathology, clinical and research based histopathology, cytopathology and in situ hybridisation.
Talks Include:

Pediatric Liver Tumors. Pearls and Pitfalls: Professor Consolato Sergi,
Professor of Pathology and Adj. Professor of Pediatrics, University of Alberta, Canada

Update in the molecular pathology of uveal melanoma:
Professor Sarah Coupland, Professor and Honorary Consultant in Pathology, University of Liverpool, UK

Implementation of personalized medicine into clinical pathology practice
Dr Gaynae Badalian-Very, Dana Farber Cancer Institute, Harvard Medical School, USA

D-Sight, The full automated platform to analyze both nuclear and membrane Immunostaining. EGFR and Ki-67 quantification in pancreas pathologies:
Dr Niccola Funel, University of Pisa, Division of Surgical Pathology, Pisa, Italy

The application of fluorescent confocal microscopy in corticosteroid-insensitive diseases:  Dr Amir Hakim, Imperial College, London, UK

Emerging role of the pathologist and cancer biomarking in as applied to stratified medicine and targeted therapy:  
Professor Bharat Jasani, Cardiff University School of Medicine, Institute of Cancer & Genetics, UK

Quantifying digital pathology in a large human brain cohort:
Dr Atticus H Hainsworth se, Stroke & Dementia Research Centre, St George’s University of London, UK

Chromogranin A- immunoreactive cells as a biomarker in the diagnosis of irritable bowel syndrome and lymphocytic colitis: Professor Magdy El-Salhy, Stord Hospital, Dept. of Clinical Medicine, Bergen University, Norway

Application of the Nanotechnology in Immunohistochemical Staining Procedures: Dr Weiming Xu, CEO London Biotech Ltd and Department of Molecular Biology and Biotechnology, University of Sheffield, UK

Companion diagnostic tests for targeted cancer treatment: advances and challenges: Professor Yao-Shan Fan,University of Miami Miller School of Medicine, Florida, USA

Molecular expression profiles of different types of thyroid carcinomas: Dr. Monika Lamba Saini,  Université catholique de Louvain,  Brussels, Belgium

Diagnosing vitamin B12 deficiency using static and functional markers: Dr Agata Sobczyńska – MaleforaViapath, St. Thomas’ Hospital, London, UK

Screening Serum Biomarkers on Cancer Patients: Using Mass Spectrometry to Answer Clinical Questions: Professor Aline M.A. Martins, Brazil

Histopathologic diagnosis in the era of new and old yeast infections in critical ill surgical patients: Assistant Professor Paola Di Carlo, Department of Sciences for Health Promotion and Mother-Child Care, University of Palermo, Italy


Different pathological outcome in guinea pigs exposed to sulphur mustard and different therapeutic possibility, Professor Mohammad Hossein Boskabady, Dept. Of Physiology, School of Medicine, Mashhad University of Medical Sciences, Iran

Role of cytopathology in steering targeted therapies in lung oncology patients: Dr Harman Sekhon, University of Ottawa, Ontario, Canada

From Eustachius to Schuknecht: What have human temporal bone pathology studies taught us: Dr. Panos Dimitriadis, Luton and Dunstable Hospital, UK

A new histological technique for examining pathological proteins at synapses in the brainDr Tara L Spires-Jones, Reader and Chancellor’s Fellow, The University of Edinburgh, Scotland

MicroRNAs and the contribution of cellular pathology to understanding their role in health and disease
Dr Anthony (Tony) Warford, Senior Lecturer in Cellular Pathology, University of Westminster, UK

Latest Euroscicon Tweets

Error: You currently have access to a subset of Twitter API v2 endpoints and limited v1.1 endpoints (e.g. media post, oauth) only. If you need access to this endpoint, you may need a different access level. You can learn more here: